Zura Bio Limited Stock Price, News & Analysis

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, reported Q2 2025 financial results and corporate updates. The company initiated TibuSHIELD, a Phase 2 study of tibulizumab for hidradenitis suppurativa, and continued progress on TibuSURE, another Phase 2 study for systemic sclerosis, with data readouts expected in Q3 2026 and Q4 2026 respectively.

Financial highlights include $154.5 million in cash and equivalents as of June 30, 2025, expected to fund operations through 2027. Q2 2025 net loss was $16.0 million ($0.17 per share), compared to $10.3 million in Q2 2024. R&D expenses increased to $8.7 million from $5.5 million year-over-year, while G&A expenses rose to $9.4 million from $6.2 million.

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has granted inducement stock options to seven new employees. The company awarded options to purchase up to 890,950 Class A Ordinary Shares, including 672,000 options to newly appointed CFO Eric Hyllengren.

The grants, approved by the Compensation Committee and Board on July 15, 2025, were made outside the company's 2023 Equity Incentive Plan as employment inducements under Nasdaq Rule 5635(c)(4). The options vest 25% initially, followed by quarterly installments of 1/12th of remaining shares, subject to continued employment.

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren will succeed Verender Badial, who will remain with the company as a non-executive employee through July 31, 2025, to ensure a smooth transition.

Hyllengren brings over 20 years of financial leadership experience in life sciences and biotechnology. He previously served as COO and CFO at Atara Biotherapeutics, where he managed strategic finance, capital markets, operational planning, and other key functions. Before that, he spent 15 years at Amgen in various roles including corporate finance, investor relations, and business development.

Badial, who joined Zura Bio in March 2023 during its business combination with JATT Acquisition Corporation, helped develop the company's financial systems and participated in capital-raising initiatives during his tenure.

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's senior leadership will deliver a corporate overview on June 4, 2025, at 3:10 PM ET in New York. The presentation will be accessible via live webcast on Zura Bio's website, with a replay available for at least 30 days afterward. Additionally, the company will engage in one-on-one meetings with investors during the conference.

Zura Bio (NASDAQ: ZURA) has launched TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS). The study will be the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in HS patients. The trial will enroll approximately 180 adults across the United States, Canada, and Europe, spanning 28 weeks with a 16-week primary efficacy assessment and 12-week safety follow-up, plus an optional open-label extension. Topline results for the primary efficacy endpoint are expected in Q3 2026. This launch follows the December 2024 initiation of TibuSURE, another Phase 2 study evaluating tibulizumab in systemic sclerosis patients.

Zura Bio (NASDAQ: ZURA) reported its Q1 2025 financial results and corporate updates. The company ended Q1 with $170.6 million in cash, expected to fund operations through 2027. Key developments include advancing the Phase 2 TibuSURE trial for tibulizumab in systemic sclerosis and preparing for a Phase 2 trial in hidradenitis suppurativa, set to begin in Q2 2025. The company reported a net loss of $17.4 million ($0.19 per share) compared to $7.7 million ($0.02 per share) in Q1 2024. R&D expenses increased to $10.5 million from $3.6 million year-over-year, while G&A expenses rose to $8.8 million from $4.8 million. The company also strengthened its team by appointing Kate Dingwall as SVP of Development Operations.

Zura Bio (NASDAQ: ZURA) reported its full year 2024 financial results, highlighting significant operational and financial achievements. The company completed a $112.5 million private placement in April 2024, ending the year with $176.5 million in cash and cash equivalents, providing runway through 2027.

Key developments include initiating the Phase 2 TibuSURE trial for systemic sclerosis and plans to launch a Phase 2 study for hidradenitis suppurativa in Q2 2025. Financial results show R&D expenses decreased to $24.4 million from $44.0 million in 2023, while G&A expenses increased to $30.8 million from $18.6 million. The company reported a net loss of $45.4 million ($0.60 per share) compared to $69.2 million ($2.09 per share) in 2023.

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. The company's senior leadership team will engage in a fireside chat on Tuesday, March 11, 2025, at 1:40 p.m. ET in Miami, FL, where they will also host investor meetings.

The presentation will be accessible through a live webcast on the News & Events page of Zura Bio's website's Investors & Media section. For those unable to attend, a replay will be available and archived on the website for a minimum of 30 days after the event.

Zura Bio (NASDAQ: ZURA) has launched TibuSURE, a global Phase 2 study evaluating tibulizumab for treating systemic sclerosis (SSc) in adults. The study marks the first clinical trial designed to investigate both anti-BAFF and IL-17 pathways in systemic sclerosis. Tibulizumab's dual-pathway approach aims to provide deeper efficacy compared to single-pathway inhibition, which has shown modest effects in rheumatic diseases like SSc.

The company believes this novel strategy of concurrently targeting two pivotal pathways involved in inflammation and fibrosis could address the multi-organ pathology of SSc, a heterogeneous and complex autoimmune disease with effective therapies currently available.